FDA Clears Sonnet BioTherapeutics’ IND Application for SON-1010
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) announced today that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for SON-1010. Shares Surge Premarket Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) gained over 79%...